US Patent

US9956171 — Liquid inhalation formulation comprising RPL554

Method of Use · Assigned to Verona Pharma Ltd · Expires 2035-09-15 · 9y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a liquid inhalation formulation containing RPL554, a pharmaceutical composition suitable for administration by inhalation.

USPTO Abstract

The present invention relates to a liquid pharmaceutical composition suitable for administration by inhalation which comprises a diluent and a suspension of particles of 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (RPL554) or a pharmaceutically acceptable salt thereof. Also described is a liquid pharmaceutical composition according to the invention for use in the treatment of the human or animal body.

Drugs covered by this patent

Ohtuvayre (ENSIFENTRINE) · Verona Pharma

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3962`	—	Ohtuvayre

Patent Metadata

Patent number: US9956171
Jurisdiction: US
Classification: Method of Use
Expires: 2035-09-15
Drug substance claim: No
Drug product claim: Yes
Assignee: Verona Pharma Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.